First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder

Sancy Leachman, Robyn P. Hickerson, Mary E. Schwartz, Emily E. Bullough, Stephen L. Hutcherson, Kenneth M. Boucher, C. David Hansen, Mark J. Eliason, G. Susan Srivatsa, Douglas J. Kornbrust, Frances J D Smith, Wh Irwin McLean, Leonard M. Milstone, Roger L. Kaspar

Research output: Contribution to journalArticle

192 Citations (Scopus)

Abstract

The rare skin disorder pachyonychia congenita (PC) is an autosomal dominant syndrome that includes a disabling plantar keratoderma for which no satisfactory treatment is currently available. We have completed a phase Ib clinical trial for treatment of PC utilizing the first short-interfering RNA (siRNA)-based therapeutic for skin. This siRNA, called TD101, specifically and potently targets the keratin 6a (K6a) N171K mutant mRNA without affecting wild-type K6a mRNA. The safety and efficacy of TD101 was tested in a single-patient 17-week, prospective, double-blind, split-body, vehicle-controlled, dose-escalation trial. Randomly assigned solutions of TD101 or vehicle control were injected in symmetric plantar calluses on opposite feet. No adverse events occurred during the trial or in the 3-month washout period. Subjective patient assessment and physician clinical efficacy measures revealed regression of callus on the siRNA-treated, but not on the vehicle-treated foot. This trial represents the first time that siRNA has been used in a clinical setting to target a mutant gene or a genetic disorder, and the first use of siRNA in human skin. The callus regression seen on the patient's siRNA-treated foot appears sufficiently promising to warrant additional studies of siRNA in this and other dominant-negative skin diseases.

Original languageEnglish (US)
Pages (from-to)442-446
Number of pages5
JournalMolecular Therapy
Volume18
Issue number2
DOIs
StatePublished - Feb 2010
Externally publishedYes

Fingerprint

Small Interfering RNA
Skin
Mutation
Bony Callus
Pachyonychia Congenita
Keratin-6
Foot
Messenger RNA
Inborn Genetic Diseases
Skin Diseases
Therapeutics
Clinical Trials
Physicians
Safety
Genes

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Genetics
  • Drug Discovery
  • Pharmacology

Cite this

Leachman, S., Hickerson, R. P., Schwartz, M. E., Bullough, E. E., Hutcherson, S. L., Boucher, K. M., ... Kaspar, R. L. (2010). First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Molecular Therapy, 18(2), 442-446. https://doi.org/10.1038/mt.2009.273

First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. / Leachman, Sancy; Hickerson, Robyn P.; Schwartz, Mary E.; Bullough, Emily E.; Hutcherson, Stephen L.; Boucher, Kenneth M.; Hansen, C. David; Eliason, Mark J.; Srivatsa, G. Susan; Kornbrust, Douglas J.; Smith, Frances J D; McLean, Wh Irwin; Milstone, Leonard M.; Kaspar, Roger L.

In: Molecular Therapy, Vol. 18, No. 2, 02.2010, p. 442-446.

Research output: Contribution to journalArticle

Leachman, S, Hickerson, RP, Schwartz, ME, Bullough, EE, Hutcherson, SL, Boucher, KM, Hansen, CD, Eliason, MJ, Srivatsa, GS, Kornbrust, DJ, Smith, FJD, McLean, WI, Milstone, LM & Kaspar, RL 2010, 'First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder', Molecular Therapy, vol. 18, no. 2, pp. 442-446. https://doi.org/10.1038/mt.2009.273
Leachman S, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Molecular Therapy. 2010 Feb;18(2):442-446. https://doi.org/10.1038/mt.2009.273
Leachman, Sancy ; Hickerson, Robyn P. ; Schwartz, Mary E. ; Bullough, Emily E. ; Hutcherson, Stephen L. ; Boucher, Kenneth M. ; Hansen, C. David ; Eliason, Mark J. ; Srivatsa, G. Susan ; Kornbrust, Douglas J. ; Smith, Frances J D ; McLean, Wh Irwin ; Milstone, Leonard M. ; Kaspar, Roger L. / First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. In: Molecular Therapy. 2010 ; Vol. 18, No. 2. pp. 442-446.
@article{a74d50ced9a44e59ba4030e45e49df15,
title = "First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder",
abstract = "The rare skin disorder pachyonychia congenita (PC) is an autosomal dominant syndrome that includes a disabling plantar keratoderma for which no satisfactory treatment is currently available. We have completed a phase Ib clinical trial for treatment of PC utilizing the first short-interfering RNA (siRNA)-based therapeutic for skin. This siRNA, called TD101, specifically and potently targets the keratin 6a (K6a) N171K mutant mRNA without affecting wild-type K6a mRNA. The safety and efficacy of TD101 was tested in a single-patient 17-week, prospective, double-blind, split-body, vehicle-controlled, dose-escalation trial. Randomly assigned solutions of TD101 or vehicle control were injected in symmetric plantar calluses on opposite feet. No adverse events occurred during the trial or in the 3-month washout period. Subjective patient assessment and physician clinical efficacy measures revealed regression of callus on the siRNA-treated, but not on the vehicle-treated foot. This trial represents the first time that siRNA has been used in a clinical setting to target a mutant gene or a genetic disorder, and the first use of siRNA in human skin. The callus regression seen on the patient's siRNA-treated foot appears sufficiently promising to warrant additional studies of siRNA in this and other dominant-negative skin diseases.",
author = "Sancy Leachman and Hickerson, {Robyn P.} and Schwartz, {Mary E.} and Bullough, {Emily E.} and Hutcherson, {Stephen L.} and Boucher, {Kenneth M.} and Hansen, {C. David} and Eliason, {Mark J.} and Srivatsa, {G. Susan} and Kornbrust, {Douglas J.} and Smith, {Frances J D} and McLean, {Wh Irwin} and Milstone, {Leonard M.} and Kaspar, {Roger L.}",
year = "2010",
month = "2",
doi = "10.1038/mt.2009.273",
language = "English (US)",
volume = "18",
pages = "442--446",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder

AU - Leachman, Sancy

AU - Hickerson, Robyn P.

AU - Schwartz, Mary E.

AU - Bullough, Emily E.

AU - Hutcherson, Stephen L.

AU - Boucher, Kenneth M.

AU - Hansen, C. David

AU - Eliason, Mark J.

AU - Srivatsa, G. Susan

AU - Kornbrust, Douglas J.

AU - Smith, Frances J D

AU - McLean, Wh Irwin

AU - Milstone, Leonard M.

AU - Kaspar, Roger L.

PY - 2010/2

Y1 - 2010/2

N2 - The rare skin disorder pachyonychia congenita (PC) is an autosomal dominant syndrome that includes a disabling plantar keratoderma for which no satisfactory treatment is currently available. We have completed a phase Ib clinical trial for treatment of PC utilizing the first short-interfering RNA (siRNA)-based therapeutic for skin. This siRNA, called TD101, specifically and potently targets the keratin 6a (K6a) N171K mutant mRNA without affecting wild-type K6a mRNA. The safety and efficacy of TD101 was tested in a single-patient 17-week, prospective, double-blind, split-body, vehicle-controlled, dose-escalation trial. Randomly assigned solutions of TD101 or vehicle control were injected in symmetric plantar calluses on opposite feet. No adverse events occurred during the trial or in the 3-month washout period. Subjective patient assessment and physician clinical efficacy measures revealed regression of callus on the siRNA-treated, but not on the vehicle-treated foot. This trial represents the first time that siRNA has been used in a clinical setting to target a mutant gene or a genetic disorder, and the first use of siRNA in human skin. The callus regression seen on the patient's siRNA-treated foot appears sufficiently promising to warrant additional studies of siRNA in this and other dominant-negative skin diseases.

AB - The rare skin disorder pachyonychia congenita (PC) is an autosomal dominant syndrome that includes a disabling plantar keratoderma for which no satisfactory treatment is currently available. We have completed a phase Ib clinical trial for treatment of PC utilizing the first short-interfering RNA (siRNA)-based therapeutic for skin. This siRNA, called TD101, specifically and potently targets the keratin 6a (K6a) N171K mutant mRNA without affecting wild-type K6a mRNA. The safety and efficacy of TD101 was tested in a single-patient 17-week, prospective, double-blind, split-body, vehicle-controlled, dose-escalation trial. Randomly assigned solutions of TD101 or vehicle control were injected in symmetric plantar calluses on opposite feet. No adverse events occurred during the trial or in the 3-month washout period. Subjective patient assessment and physician clinical efficacy measures revealed regression of callus on the siRNA-treated, but not on the vehicle-treated foot. This trial represents the first time that siRNA has been used in a clinical setting to target a mutant gene or a genetic disorder, and the first use of siRNA in human skin. The callus regression seen on the patient's siRNA-treated foot appears sufficiently promising to warrant additional studies of siRNA in this and other dominant-negative skin diseases.

UR - http://www.scopus.com/inward/record.url?scp=76349084709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=76349084709&partnerID=8YFLogxK

U2 - 10.1038/mt.2009.273

DO - 10.1038/mt.2009.273

M3 - Article

C2 - 19935778

AN - SCOPUS:76349084709

VL - 18

SP - 442

EP - 446

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 2

ER -